ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3055

Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricaemia: Comparison with Normouricaemic Individuals

Sarah Stewart1, Nicola Dalbeth2,3, Alain Vandal4, Bruce Allen5, Rhian Miranda6 and Keith Rome7, 1School of Podiatry, Auckland University of Technology, Auckland, New Zealand, 2Auckland District Health Board, Auckland, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand, 4Counties Manukau District Health Board, Auckland, New Zealand, 5Horizon Radiology, Auckland, New Zealand, 6Auckland City Hospital Radiology, Auckland, New Zealand, 7School of Clinical Sceince, Health & Rehabilitation Research Institute, AUT University, Auckland, New Zealand

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: foot, gout and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The first metatarsophalangeal joint (1MTPJ) is frequently affected in gout. This study aimed to identity ultrasound features of the 1MTPJ in people with gout and people with asymptomatic hyperuricaemia compared with normouricaemic controls.

Methods: Participants with gout (n=23), asymptomatic hyperuricaemia (n=29) and age- and sex-matched normouricaemic control participants (n=34) underwent a grey-scale and power Doppler ultrasound assessment of both 1MTPJs using a Phillips iU22 ultrasound machine with a 10 MHz, 55mm linear array transducer. No participants had clinical evidence of gout flare at the time of scanning. The images were assessed by two blinded independent radiologists for the presence of the double contour sign, tophus, erosion, effusion, synovial hypertrophy, and synovitis. Cartilage thickness and tophus diameter were also measured. Inter-reader reliability was assessed using Cohen’s kappa (ƙ) and intra-class correlation coefficients (ICC). Binary logistic and linear regression models were used to determine between-group differences in the ultrasound features. A stepwise linear regression was used to determine which ultrasound features were independently associated with gout compared with asymptomatic hyperuricaemia.

Results: Inter-reader reliability was moderate for the presence of the double contour sign, tophus, erosion, synovial hypertrophy and effusion (ƙ=0.42 to 0.59), good for synovitis (ƙ=0.66) and excellent for cartilage thickness and tophus diameter (ICC=0.81 and 0.86 respectively). Compared to normouricaemic control participants, participants with gout and with asymptomatic hyperuricaemia had more frequent double contour sign (Table, odds ratio (OR) 3.91, P=0.011 and OR 3.81, P=0.009, respectively). Participants with gout also had more erosion (OR 10.13, P=0.001) and synovitis (OR 9.00, P<0.001) and had greater tophus diameter (0.00mm vs. 1.68mm, P=0.035). There was no significant difference in cartilage thickness between groups. More severe erosion and synovitis grades and a less severe effusion grade were independently associated with a diagnosis of gout compared with asymptomatic hyperuricaemia (R2 for model = 0.65, p < 0.001).

Conclusion: Urate deposition, synovitis and bone erosion are common at the 1MTPJ in people with gout, even in the absence of flare. Furthermore, although individuals with asymptomatic hyperuricemia lack ultrasound features of inflammation or structural joint changes, they demonstrate a similar frequency of urate deposition. These data support the concept that gout is a disease of chronic inflammation in response to intra-articular urate crystal deposition.

Table. Odds ratios for the presence of ultrasound features at the 1MTPJ

Present,    n (%)

Odds Ratio†

95% CI for OR

p

Lower

Upper

Double Contour Sign

Control

9 (13%)

Gout

17 (37%)

3.91

1.37

11.20

0.011

AH

21 (36%)

3.81

1.41

10.36

0.009

Tophus

Control

0 (0%)

Gout

6 (13%)

5.08

0.96

27.08

0.057

AH

0 (0%)

1.00

0.12

8.26

1.000

Erosion

Control

2 (3%)

Gout

15 (33%)

10.13

2.75

37.28

0.001

AH

1 (2%)

0.83

0.14

4.88

0.83

Effusion

Control

12 (18%)

Gout

4 (9%)

0.45

0.13

1.61

0.22

AH

13 (22%)

1.34

0.51

3.54

0.55

Synovial hypertrophy

Control

0 (0%)

Gout

1 (2%)

3.25

0.67

15.73

0.14

AH

2 (3%)

1.72

0.32

9.13

0.52

Synovitis

Control

5 (7%)

Gout

20 (44%)

9.00

3.10

26.08

<0.001

AH

2 (3%)

0.60

0.14

2.69

0.51

†Reference category: control group; AH = Asymptomatic hyperuricaemia


Disclosure: S. Stewart, None; N. Dalbeth, None; A. Vandal, None; B. Allen, None; R. Miranda, None; K. Rome, None.

To cite this abstract in AMA style:

Stewart S, Dalbeth N, Vandal A, Allen B, Miranda R, Rome K. Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricaemia: Comparison with Normouricaemic Individuals [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/ultrasound-features-of-the-first-metatarsophalangeal-joint-in-gout-and-asymptomatic-hyperuricaemia-comparison-with-normouricaemic-individuals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-features-of-the-first-metatarsophalangeal-joint-in-gout-and-asymptomatic-hyperuricaemia-comparison-with-normouricaemic-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology